https://www.clinicaltrialsarena.com/news/newstsc-recommends-helix-begin-phase-ii-component-ldos002-nsclc-study-4873525/
TSC recommends Helix to begin Phase II component of LDOS002 NSCLC study - Clinical Trials Arena
Apr 24, 2016 - The Trial Steering Committee (TSC) has recommended Helix BioPharma (Helix), a clinical stage biopharmaceutical company, to begin a Phase II portion of LDOS002...